Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immunotherapy after Chemo-Radiation shows promise for lung cancer

NCT ID NCT07161388

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 3 times

Summary

This study looks at whether the immunotherapy drug durvalumab can help people with limited-stage small-cell lung cancer when given after chemoradiation. Researchers will track 200 patients in China to see how long the cancer stays under control and how safe the treatment is. The goal is to understand real-world effectiveness outside of a controlled trial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
durvalumab (an immunotherapy drug)
What this could lead to
If successful, this could show that durvalumab helps delay cancer progression after standard chemoradiation for limited-stage small-cell lung cancer.
What could go wrong
This is an observational study, not a randomized trial, so results may be less definitive. Side effects of immunotherapy can include inflammation of organs, and the study is still recruiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult male or female patients (with age ≥18 years old) who able to provide informed consent received platinum-based cCRT/sCRT followed by durvalumab consolidation as first-line treatment at the discretion of physicians and no disease progression following cCRT/sCRT

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able to provide informed consent * Age ≥18 years * Histologically or cytologically documented LS-SCLC (Stage I-III SCLC \[T any, N any, M0\] according to the American Joint Committee on Cancer Staging Manual \[AJCC Cancer Staging Manual, 8th Edition\], that can be safely treated with definitive radiation doses. Excludes T3-4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan) * ECOG PS 0-2 (prior to the first dose of durvalumab after CRT) * No disease progression following cCRT/sCRT (cCRT refers to chemotherapy and radiotherapy are administered with overlap; sCRT refers to chemotherapy and radiotherapy are delivered in a sequential manner with no overlap) * Patients who received platinum-based cCRT/sCRT followed by durvalumab consolidation as first-line treatment at the discretion of physicians are eligible (the time interval from the end of cCRT/sCRT to the first dose of durvalumab consolidation should be within 3 months) * Patients who started durvalumab consolidation ≤3 months before enrolment in the study will be allowed (irrespective of whether they continue to receive durvalumab at time of enrolment or already discontinued treatment) Exclusion Criteria: * Patients treated with CRT only without subsequent durvalumab consolidation * Patients received durvalumab or any other anti-PD-1/anti-PD-L1 antibodies along with CRT * Patients who previously were involved, or currently are, or plan to be involved in any other interventional anti-cancer clinical studies for LS-SCLC * Prior exposure to immune-mediated therapy including, but not limited to, other anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies, excluding therapeutic anticancer vaccines * Judgment by the investigator that the patient should not participate in the study because the patient is unlikely to comply with study procedures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Limited stage small-cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Limited stage small-cell lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    20 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    RECRUITING

    Beijing, China

  • Research Site

    RECRUITING

    Cangzhou, China

  • Research Site

    RECRUITING

    Dongguan, China

  • Research Site

    RECRUITING

    Fuzhou, China

  • Research Site

    RECRUITING

    Guangzhou, China

  • Research Site

    RECRUITING

    Huzhou, China

  • Research Site

    RECRUITING

    Jinan, 250117, China

  • Research Site

    RECRUITING

    Jinan, China

  • Research Site

    RECRUITING

    Nanjing, China

  • Research Site

    RECRUITING

    Nanning, China

  • Research Site

    RECRUITING

    Ningbo, China

  • Research Site

    RECRUITING

    Shanghai, China

  • Research Site

    RECRUITING

    Shenyang, China

  • Research Site

    RECRUITING

    Shijiazhuang, China

  • Research Site

    RECRUITING

    Taiyuan, China

  • Research Site

    RECRUITING

    Tianjing, China

  • Research Site

    TERMINATED

    Tianjing, China

  • Research Site

    RECRUITING

    Wuhan, China

  • Research Site

    RECRUITING

    Wuxi, China

  • Research Site

    RECRUITING

    Yangzhou, China

  • Research Site

    RECRUITING

    Zhengzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.